Ocugen (NASDAQ:OCGN) Trading Down 7.2% - Here's Why

Key Points

• Q4 results showed an EPS loss of $0.06 (in line) but revenue plunged to -$0.19M versus an expected $0.86M, with a reported $17.7M loss and extremely negative margins—fundamentals that can keep pressure on the stock.
• Ocugen outlined a clear regulatory path including a planned 2026 BLA submission and three pivotal filings within three years, and completed enrollment in the OCU400 Phase 3 trial with topline data expected in Q1 2027, which are potential value-driving catalysts if successful.
• Analyst sentiment is mixed but bullish in parts: Chardan reaffirmed a "buy" with a $7 price target (consensus target ~$7) while the stock traded down ~7.2% to about $1.82, highlighting large upside expectations amid high volatility.

Ocugen, Inc. (NASDAQ:OCGN - Get Free Report)'s share price was down 7.2% on Thursday . The company traded as low as $1.79 and last traded at $1.8180. Approximately 2,458,987 shares changed hands during trading, a decline of 57% from the average daily volume of 5,723,533 shares. The stock had previously closed at $1.96.

Key Headlines Impacting Ocugen

Here are the key news stories impacting Ocugen this week:

• Positive Sentiment: Chardan Capital reaffirmed a "buy" rating and set a $7.00 price target (implying large upside from current levels), which can attract speculative buying and institutional interest. Benzinga
• Positive Sentiment: Ocugen outlined plans for a 2026 BLA submission and expects three pivotal filings within three years, and said it is expanding leadership — a clear near- to mid-term regulatory pathway that could materially increase valuation on successful filings. Seeking Alpha
• Positive Sentiment: Enrollment for the OCU400 Phase 3 liMeliGhT trial (gene therapy for broad retinitis pigmentosa) is complete; topline Phase 3 data are expected in Q1 2027 — a major clinical milestone that could be value-driving if positive. GlobeNewswire
• Neutral Sentiment: Market commentary and press coverage highlighted stock movement after results (e.g., "Gains on Results"); this reflects short-term volatility as investors parse the mixed financials and development updates. BayStreet
• Neutral Sentiment: The full Q4 2025 earnings call transcript is available for investors to review management's commentary and Q&A (useful for assessing cadence on spend, milestones, and timelines). Earnings Call Transcript
• Negative Sentiment: Q4 results: EPS loss of $0.06 (in line) but revenue came in negative/was substantially below expectations (reported -$0.19M vs. est. $0.86M), and the quarter showed a $17.7M loss with very negative margins and ROE — fundamentals that can pressure the stock until revenue/expense trends improve. Press Release

Wall Street Analyst Weigh In

OCGN has been the subject of several recent research reports. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Ocugen in a report on Thursday, January 22nd. Chardan Capital restated a "buy" rating and issued a $7.00 target price on shares of Ocugen in a research note on Thursday. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $7.00.

Ocugen Price Performance

The company has a debt-to-equity ratio of 8.04, a current ratio of 1.85 and a quick ratio of 1.85. The company's 50 day moving average is $1.57 and its 200 day moving average is $1.42. The stock has a market cap of $537.22 million, a price-to-earnings ratio of -7.82 and a beta of 2.75.

Ocugen (NASDAQ:OCGN - Get Free Report) last issued its earnings results on Wednesday, March 4th. The company reported ($0.06) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.06). The company had revenue of ($0.19) million during the quarter, compared to analysts' expectations of $0.86 million. Ocugen had a negative net margin of 1,192.18% and a negative return on equity of 491.22%. Research analysts forecast that Ocugen, Inc. will post -0.2 earnings per share for the current fiscal year.

Institutional Trading of Ocugen

Several large investors have recently bought and sold shares of OCGN. Caitong International Asset Management Co. Ltd raised its stake in shares of Ocugen by 76,831.8% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 82,317 shares of the company's stock worth $111,000 after buying an additional 82,210 shares during the last quarter. Virtu Financial LLC acquired a new stake in shares of Ocugen in the fourth quarter valued at approximately $106,000. NewEdge Advisors LLC increased its stake in shares of Ocugen by 69.0% during the 4th quarter. NewEdge Advisors LLC now owns 135,460 shares of the company's stock worth $183,000 after purchasing an additional 55,305 shares in the last quarter. Millennium Management LLC raised its position in shares of Ocugen by 29.7% during the 4th quarter. Millennium Management LLC now owns 5,396,417 shares of the company's stock worth $7,285,000 after purchasing an additional 1,234,268 shares during the last quarter. Finally, Balyasny Asset Management L.P. purchased a new stake in Ocugen in the 4th quarter valued at approximately $196,000. Institutional investors and hedge funds own 10.27% of the company's stock.

About Ocugen

Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gene therapies to treat rare inherited retinal diseases, as well as vaccines designed to address unmet needs in infectious diseases. Headquartered in Malvern, Pennsylvania, the company applies its proprietary gene therapy platform to create novel treatments aimed at preserving and restoring vision, while leveraging strategic partnerships to broaden its vaccine pipeline.

In its gene therapy portfolio, Ocugen is advancing multiple programs targeting retinal disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.